What is Stereotaxis Inc (STXS) stock price today?

Stereotaxis Inc (STXS) currently trades at $1.87 per share. The stock has a market capitalization of $188.13M and a P/E ratio of —x.

Is STXS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Stereotaxis Inc has a Smart Value Score of 34/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Stereotaxis Inc's revenue and earnings?

Stereotaxis Inc has trailing twelve-month (TTM) revenue of $32.38M with profit margins of -66.80%. Earnings per share (EPS) is $-0.25.

Is STXS stock overvalued or undervalued?

Based on our DCF model, Stereotaxis Inc's intrinsic value is $3.66, representing a margin of safety of 44.54%. The stock currently trades at a P/E of —x.

STXS

Stereotaxis Inc

NYSE MKT: STXS · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$1.87

+2.75% today

Updated 2026-04-30

Market cap

$188.13M

P/E ratio

—

P/S ratio

5.81x

EPS (TTM)

$-0.25

Dividend yield

—

52W range

$2 – $4

Volume

0.4M

Market cap

$188.13M

P/E ratio

—

P/S ratio

5.81x

EPS (TTM)

$-0.25

Dividend yield

—

52W range

$2 – $4

Volume

0.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.0

Growth

5.0

Quality

C+

2.0

Profitability

7.0

Valuation

B+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$4.20

+124.60%

12-Month target

—

Intrinsic (DCF)

$3.66

Margin of safety

+44.54%

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 36.30% QoQ

+ 44.54% below intrinsic value

Risks

- Thin margins at -66.80%

- Negative free cash flow $-4.04M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$28.15M	$26.77M	$26.92M	$32.38M	$32.38M
Net income	$-19.15M	$-20.71M	$-24.05M	$-21.64M	$-5.53M
EPS	—	—	—	—	$-0.25
Free cash flow	$-10.79M	$-9.51M	$-8.53M	$-13.78M	$-4.04M
Profit margin	-68.04%	-77.37%	-89.33%	-66.85%	-66.80%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
STXS	$188.13M	34	6.0	2.0	7.0	5.0	+44.54%	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Stereotaxis Inc trades at $1.87. Our Smart Value Score of 34/100 indicates the stock is weak. TTM revenue stands at $32.38M. with profit margins at -66.80%. Our DCF model estimates intrinsic value at $3.66.

Frequently asked questions

What is Stereotaxis Inc's stock price?

Stereotaxis Inc (STXS) trades at $1.87.

Is Stereotaxis Inc overvalued?

Smart Value Score 34/100 (Grade F, Strong Sell). DCF value $3.66.

What is the price target of Stereotaxis Inc (STXS)?

The analyst target price is $4.20, representing +124.6% upside from the current price of $1.87.

What is the intrinsic value of Stereotaxis Inc (STXS)?

Based on our DCF model, intrinsic value is $3.66, a +44.5% margin of safety versus $1.87.

What is Stereotaxis Inc's revenue?

TTM revenue is $32.38M.

Company info

SectorHEALTHCARE

IndustryMEDICAL INSTRUMENTS & SUPPLIES

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

Quick metrics

P/S ratio5.81x

ROE-143.60%

Beta1.42

50D MA$1.97

200D MA$2.45

Shares out0.10B

Float0.07B

Short ratio—

Avg volume0.4M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

STXS vs LLY →STXS vs JNJ →STXS vs ABBV →Stock screener →